Ajanta Pharma has submitted a revised schedule for its upcoming analyst and institutional investor meetings to the stock exchanges. The company clarified that the dates for two conferences were inadvertently interchanged in its earlier intimation. The corrected schedule confirms meetings in May and June 2026, allowing investors to engage with the management.

Meeting Schedule

The company has provided the following updated details for the events. The first conference is now set for late May, followed by the second in early June.

Disclosure Details

The intimation was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ajanta Pharma noted that the schedule for these meetings remains subject to change due to exigencies on either side.

Furthermore, the company explicitly confirmed that any discussion during these meetings will be strictly on the basis of already published information. The disclosure was digitally signed by Gaurang Shah, Sr. VP - Legal & Company Secretary, on May 19, 2026.

Ajanta Pharma Limited received a disclosure dated 13 May 2026 from promoter Aayush Agrawal, trustee of the Aayush Agrawal Trust, regarding the creation and release of a pledge on 2,86,213 shares of the company. The disclosure was filed with BSE and NSE in accordance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Creation and Release Details

Both the pledge creation and its release took place on 12 May 2026, with Julius Baer Capital (India) Pvt Ltd named as the entity in whose favour the shares were encumbered. The pledge was created to secure a new loan, and was subsequently released upon repayment of the said loan. The following table summarises the key details of the encumbrance events:

Pre and Post-Event Encumbrance Position

Prior to the pledge creation, Aayush M Agrawal (trustee, Aayush Agrawal Trust) held 87,81,662 shares already encumbered, representing 7.03% of the total share capital. Following the pledge creation of 2,86,213 shares, the encumbered holding rose to 90,67,875 shares (7.26%). After the subsequent release of 2,86,213 shares, the encumbered holding reverted to 87,81,662 shares, or 7.03% of total share capital. The total promoter holding of Aayush M Agrawal (trustee, Aayush Agrawal Trust) stands at 1,41,12,924 shares, representing 11.30% of the total share capital.

Promoter Group Shareholding Overview

The disclosure also provides a snapshot of the broader promoter group's shareholding as on the reporting date. The table below captures the holdings of all promoters and persons acting in concert (PACs):

Regulatory Compliance

The disclosure was submitted by Aayush Agrawal in his capacity as trustee of the Aayush Agrawal Trust and addressed to both BSE Limited and the National Stock Exchange of India. A copy was also forwarded to the Company Secretary of Ajanta Pharma Limited at its registered office in Mumbai. The filing is in compliance with the prescribed format under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and was reported on 13 May 2026.